# High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

> **NCT01534143** · PHASE2 · TERMINATED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 1 (actual)

## Conditions studied

- Refractory Multiple Myeloma
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma

## Interventions

- **OTHER:** pharmacological study
- **DRUG:** tacrolimus
- **DRUG:** sirolimus
- **BIOLOGICAL:** anti-thymocyte globulin
- **DRUG:** fludarabine phosphate
- **DRUG:** busulfan
- **DRUG:** bortezomib
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01534143
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-02
- **Primary completion:** 2013-05
- **Final completion:** 2013-05
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Data was not collected, because funding was unavailable to continue study.
- **Last updated:** 2017-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01534143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01534143, "High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01534143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*